Skip to main content Skip to main navigation menu Skip to site footer

Serum markers of Inflammatory Bowel Disease: A literature review

  • Siti Muchayat Purnamaningsih ,


Abstract

Background: The diagnosis, prognosis, assessment of disease activity and severity, as well as the outcome of therapy of inflammatory bowel disease (IBD), Crohn’s disease (CD), and ulcerative colitis (UC), remain a challenge for physicians treating this disorder. For each of these aspects, there is no single gold standard test or examination. Endoscopy accompanied by histology examination can confirm the diagnosis of IBD. Laboratory markers have been investigated in IBD for diagnostic and differential diagnostic purposes, assessment of disease activity and risk of complications, prediction of relapse, and for monitoring the effect of therapy. Objective: This article provides a review of the literature regarding IBD with the recommendation of prominent markers that can be used for diagnosing and monitoring the disease. Conclusion: C-reactive protein is an acute phase reactant which is best used to assess inflammation in IBD. Fecal calprotectin and lactoferrin are reliable fecal markers to monitor disease activity. The combination of serological marker P-ANCA and ASCA can be used to diagnose CD. In clinical practice, Crohn's Disease Activity Index (CDAI) is used as the primary tool for evaluating IBD. 

Keywords: IBD CRP calprotectin lactoferrin P-ANCA ASCA CDAI

References

  1. Bing XIA., Crusius JBA, Meuwissen SGM, Pena AS. Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies. WJG. 1998;4(5):446-458
  2. Danese S, Fiocchi C. Ulcerative Colitis. N Engl J Med. 2011. 365:1713­25
  3. Wyeth J. Crohn’s disease and ulcerative colitis. BPJ. Issue 16: 34-38
  4. Vermeire S, Van Assche G, Rutgeerts P. Recent advances in clinical practice laboratory. Laboratory markers in IBD: useful, magic, or unnecessary toys?. GUT. 2006. 55: 426-431
  5. Paduchova Z, Durackova Z. Fecal calprotectin as a promising marker of inflammatory diseases. Bratisl Lek Listy. 2009. 110 (10): 598-602
  6. Bamias G, Nyce MR, Rue SA, Cominelli F. New Concepts in the Pathophysiology of Inflammatory Bowel Disease. Ann Intern Med. 2005. 143:895-904
  7. Anonymous. Crohn’s Disease. Available at https://www.google.com/#psj=1&q=crohn%27s+ Disease + wikipedia
  8. Weiss G, Gasche C. Pathogenesis and treatment of anemia in inflammatory bowel disease. Haematologica. 2010. 95(2): 175-178
  9. Oustamanolakis P, Koutroubakis IE, Messaritakis I, Malliaraki N, Sfiridaki A, Kouroumalis EA. Serum hepcidin and prohepcidin concentrationsin inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011 Mar. 23(3):262-8
  10. Bergamaschi G, et al. Serum hepcidin in inflammatory bowel diseases: biological and clinical significance. Inflamm Bowel Dis. 2013.. 19(10):2166-72
  11. Vermeire S, Assche GV, Rutgeerts P. C-Reactive Protein as a Marker for InflammatoryBowel Disease.Inflamm Bowel Dis. 2004. 10 (5): 661-665
  12. Vieira A et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes. 2009. 2(221): 1-7
  13. Turkay C, Kasapoglu B. Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update. CLINICS. 2010. 65 (2): 221-31
  14. Bossuyt X. Serologic Markers in Inflammatory Bowel Disease. Clinical Chemistry. 2006. 52 (2): 171–181
  15. Kaul A, Hutfless S, Liu L, Marohn MR, Li X, Bayless TM. Serum Anti-glycan Antibody Biomarkers for Inflammatory Bowel Disease Diagnosis and Progression: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2011. 000:000–000
  16. Xie Q, Gan HT. Controversies about the use of serological markers in diagnosis of inflammatory bowel disease.World J Gastroenterol . 2010. 16(2): 279-280
  17. Song WB, et al. Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease. World J Gastroenterol. 2009. 15(31): 3916-3919
  18. Herfarth H. A Reassessment of the CDAI as an Index of Crohn’s Disease. AGAPerspektif. 2013. April/ May, 9 (2): 4,6
  19. Cohen CD. Should Mucosal healing Be used Instead?. AGA Perspektif. 2013. April/May, 9(2): 5,7
  20. Schroeder KW et al. Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis. N Engl J Med. 1987. 317:1625-9

How to Cite

Purnamaningsih, S. M. (2018). Serum markers of Inflammatory Bowel Disease: A literature review. Bali Medical Journal, 7(2). https://doi.org/10.15562/bmj.v7i2.887
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
2

Total
2

Share

Search Panel

Siti Muchayat Purnamaningsih
Google Scholar
Pubmed
BMJ Journal